Inovio Pharmaceuticals Inc expected to post a loss of $1.15 a share - Earnings Preview

Inovio Pharmaceuticals

13/11/2024 24:02

* Inovio Pharmaceuticals Inc  INO.OQ   INO.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
14 for the period ending September 30 2024
    * The San Diego California-based  company is expected to
report a
73.1% decrease in revenue to $104.5 thousand from $388 thousand
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Inovio Pharmaceuticals
Inc is
for a loss of $1.15 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inovio
Pharmaceuticals Inc is 13.50​, above​ its last closing price
of $5.15. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -1.12       -1.10      -1.19     Missed  -8
 Jan. 1 2024   -1.01       -1.00      -1.31     Missed  -30.6
 Dec. 31 2023  -1.42       -1.27      -1.12     Beat    11.6​
 Sep. 30 2023  -1.50       -1.52      -1.56     Missed  -2.6
 ​​Jun.        -1.81       -1.74      -1.56     Beat    10.3
 30 2023                                                
 Jan. 1 0001   -1.76       -1.74      -1.92     Missed  -10.3​
 Dec. 31 2022  -2.01       -2.02      -2.52     Missed  -25
 Sep. 30 2022  -3.56       -3.55      -1.80     Beat    49.3
 This summary was machine generated November 13 at 00:02 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)